Breast Cancer News

CancerConnect breast cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of breast cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of breast cancer treatment and survivorship.

Share

Breast Cancer News


Breast cancer treatment with fewer potential side effects has equally good patient outcomes, UCLA study shows (July 2, 2015)

A new study by UCLA scientists has found that women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy,... Continue Reading

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer (June 9, 2015)

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings... Continue Reading

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer (June 3, 2015)

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor... Continue Reading

Combination of Iniparib, Gemzar®, and Carboplatin Active in Initial Treatment of Early-Stage Triple-Negative Breast Cancer (June 2, 2015)

The combination of iniparib, Gemzar® (gemcitabine), and carboplatin appears promising in the initial treatment of patients with early-stage triple-negative breast cancer with a BRCA1/2 mutation. In addition,... Continue Reading

Platinum-Based Chemotherapy Active in Metastatic Triple-Negative Breast Cancer (May 26, 2015)

Platinum-based chemotherapy appears active in the treatment of metastatic triple-negative breast cancers, particularly among patients with a BRCA1/2 mutation. These findings were reported in the Journal... Continue Reading

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer (April 30, 2015)

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved... Continue Reading

The Importance of Awareness of Breast Density and Its Impact on Cancer Screening and Risk (April 23, 2015)

Women in the United States may not be adequately aware of breast density and its complications. Legislation that requires providers to discuss a woman’s breast density is likely to help build awareness.... Continue Reading

Most Women with Early-Stage Breast Cancer Avoid Extensive Lymph Node Removal, Showing Increasing Adherence to Scientific Evidence that a Radical Operation Is No Longer Necessary (April 6, 2015)

NEWS FROM THE AMERICAN COLLEGE OF SURGEONS  CHICAGO (March 26, 2015): A new study of women with early-stage breast cancer finds that surgeons no longer universally remove most of the lymph nodes in the... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (March 24, 2015)

CancerConnect News: In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (March 9, 2015)

CancerConnect News: Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer... Continue Reading

More Breast Cancer News

Latest Breast Cancer News By Stage


Screening and Prevention

The Importance of Awareness of Breast Density and Its Impact on Cancer Screening and Risk (April 23, 2015)

Women in the United States may not be adequately aware of breast density and its complications. Legislation that requires providers to discuss a woman’s breast density is likely to help build awareness. These findings were reported in the Journal of... Continue Reading

Low-Fat Diet May Help Prevent Certain Breast Cancers (February 4, 2015)

Women who lower their fat intake may have a reduced risk of estrogen receptor (ER)-positive/progesterone receptor (PR)-negative breast cancer. These findings were published in Cancer Epidemiology, Biomarkers & Prevention. The relationship between... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Breakthrough Mayo Clinic Study Confirms Molecular Breast Imaging (MBI) High Absolute Sensitivity for Supplemental, Low-Dose Screening Studies in Women with Dense Breast Tissue (January 26, 2015)

A breakthrough study conducted by Mayo Clinic and published in the AJR has clinically confirmed that Molecular Breast Imaging (MBI) yields superior imaging and low radiation exposure for women with dense breast tissue, which can affect up to 40% of the... Continue Reading

IBIS-I Trial Confirms Greater Than Fifteen Year Benefit of Tamoxifen to Reduce Risk of Breast Cancer in High-Risk Women (December 16, 2014)

CancerConnect News: Long term results of the International Breast Cancer Intervention Study-I (IBIS-I) were presented at the 2014 San Antonio Breast Cancer Symposium, confirming that tamoxifen significantly decreased the risk of developing breast cancer... Continue Reading

More Screening and Prevention

Carcinoma in Situ

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer (June 9, 2015)

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Ask the Early-Stage Breast Cancer Expert: Now Available (October 23, 2014)

Rethink Pink: From Awareness to Knowledge, Advice for women newly diagnosed with early stage breast cancer Live Web Chat with Dr. Yashar: Recorded 10/23 Awareness of breast cancer risk and appreciation of the need for screening is important, but at this... Continue Reading

October Is National Breast Cancer Awareness Month (October 10, 2014)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 23rd at 6pm EDT, we will have a live web chat with UC San Diego Moores Cancer Center... Continue Reading

Walk or Run Your Way to a Reduced Risk of Breast Cancer (September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading

More Carcinoma in Situ

Stage I - Node Negative

Breast cancer treatment with fewer potential side effects has equally good patient outcomes, UCLA study shows (July 2, 2015)

A new study by UCLA scientists has found that women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy, saw no increase in cancer recurrence or difference... Continue Reading

Combination of Iniparib, Gemzar®, and Carboplatin Active in Initial Treatment of Early-Stage Triple-Negative Breast Cancer (June 2, 2015)

The combination of iniparib, Gemzar® (gemcitabine), and carboplatin appears promising in the initial treatment of patients with early-stage triple-negative breast cancer with a BRCA1/2 mutation. In addition, researchers have found ways to identify patients... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Study Confirms Role of Ovarian Suppression and Aromasin for Younger Women With Hormone-sensitive Breast Cancer (December 19, 2014)

CancerConnect News: Ovarian suppression combined with the anti-estrogen drug Aromasin® (exemestane) appears to greatly reduce the risk of breast cancer recurrence in younger women according to the results of the Suppression of Ovarian Function Trial... Continue Reading

Breast Cancer Patients Are Now Living Longer without Relapse (December 18, 2014)

CancerConnect News: Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical... Continue Reading

More Stage I Node Negative

Stages II-III

Dose-Dense Chemotherapy with Ellence®, Cytoxan®, and Taxol® May Improve Survival in Node-Positive Breast Cancer (April 30, 2015)

Patients with early-stage node-positive breast cancer who receive dose-dense adjuvant chemotherapy with Ellence® (epirubicin), Cytoxan® (cyclophosphamide), and Taxol® (paclitaxel) may have improved disease-free survival. These findings were released... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (March 24, 2015)

CancerConnect News: In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer... Continue Reading

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer (February 27, 2015)

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer progression when used as first-line treatment... Continue Reading

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer (February 5, 2015)

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings were presented at the 2014 San Antonio... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

More Stages II and III

Inflammatory

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

October Is National Breast Cancer Awareness Month (October 10, 2014)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 23rd at 6pm EDT, we will have a live web chat with UC San Diego Moores Cancer Center... Continue Reading

Walk or Run Your Way to a Reduced Risk of Breast Cancer (September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Making Informed Decisions about Breast Reconstruction, featuring an expert from Memorial Sloan Kettering Cancer Center (July 16, 2014)

Memorial Sloan Kettering Cancer Center expert Andrea L. Pusic, MD, MHS, FRCSC, discussed and answered participants’ questions about reconstruction after breast cancer surgery during a live Web chat on July 16, 2014. The recorded version of the Web... Continue Reading

More Inflammatory

Metastatic

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer (June 3, 2015)

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These... Continue Reading

Platinum-Based Chemotherapy Active in Metastatic Triple-Negative Breast Cancer (May 26, 2015)

Platinum-based chemotherapy appears active in the treatment of metastatic triple-negative breast cancers, particularly among patients with a BRCA1/2 mutation. These findings were reported in the Journal of Clinical Oncology. Breast cancers that are not... Continue Reading

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer (March 24, 2015)

CancerConnect News: In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (March 9, 2015)

CancerConnect News: Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival... Continue Reading

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (March 5, 2015)

CancerConnect News:  The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and... Continue Reading

More Metastatic

Recurrent

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (March 9, 2015)

CancerConnect News: Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival... Continue Reading

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (March 5, 2015)

CancerConnect News:  The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and... Continue Reading

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer (February 5, 2015)

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings were presented at the 2014 San Antonio... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Breast Cancer Patients Are Now Living Longer without Relapse (December 18, 2014)

CancerConnect News: Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical... Continue Reading

More Recurrent

Supportive Care

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

October Is National Breast Cancer Awareness Month (October 10, 2014)

What does breast cancer awareness month mean to you? We’d like to hear from you—join us on facebook, twitter, or CancerConnect and join the discussion. On October 23rd at 6pm EDT, we will have a live web chat with UC San Diego Moores Cancer Center... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Making Informed Decisions about Breast Reconstruction, featuring an expert from Memorial Sloan Kettering Cancer Center (July 16, 2014)

Memorial Sloan Kettering Cancer Center expert Andrea L. Pusic, MD, MHS, FRCSC, discussed and answered participants’ questions about reconstruction after breast cancer surgery during a live Web chat on July 16, 2014. The recorded version of the Web... Continue Reading

Ask the Expert: Breast Cancer, Diet and Exercise (May 19, 2014)

CancerConnect recently partnered with Dana-Farber to provide you with the opportunity to engage with a breast cancer expert, Jennifer A. Ligibel, MD, of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. On May 7 and 8, 2014, Dr. Ligibel... Continue Reading

More Supportive Care

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS